论文部分内容阅读
目的探讨厄贝沙坦和卡维地洛联合用药以及单用厄贝沙坦对慢性充血性心力衰竭(CHF)患者临床症状及左室功能的改善情况。方法采用多中心随机双盲平行对照,将50名2～3级慢性CHF患者随机分为厄贝沙坦联用卡维地洛组(治疗组)30例,厄贝沙坦组(对照组)20例。两组病例均进行为期12周的治疗观察。结果治疗组总有效率高于对照组(P<0.05)。不良反应发生率差异无统计学意义;主要的不良反应均为头晕和上腹不适,但程度均轻微。结论厄贝沙坦和卡维地洛联用对治疗心功能为2～3级的慢性CHF患者是较为合理安全有效的组合,优于单用厄贝沙坦。
Objective To investigate the clinical symptoms and the improvement of left ventricular function in patients with chronic congestive heart failure (CHF) by combination therapy of irbesartan and carvedilol and irbesartan alone. Methods Fifty patients with grade 2 or 3 chronic CHF were randomly divided into irbesartan and carvedilol group (treatment group) 30 cases, irbesartan group (control group) 20 cases. Two groups of patients were treated for a period of 12 weeks of observation. Results The total effective rate of the treatment group was higher than that of the control group (P <0.05). The incidence of adverse reactions was not statistically different; the main adverse reactions were dizziness and abdominal discomfort, but to a lesser extent. Conclusion The combination of irbesartan and carvedilol is a reasonable and safe combination for the treatment of chronic CHF patients with grade 2 to 3 heart function, which is superior to irbesartan alone.